Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

The move comes after Novo Nordisk’s share price fell 50% over the last 12 months, and amid growing pressure from the powerful Novo Nordisk Foundation, which controls the company’s voting majority.

Novo’s weight-loss drugs are administered by injection and a pill version would be more convenient for patients, ... Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills.

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...

Ozempic maker Novo Nordisk NOVO.B-0.35%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...

Jørgensen, who joined Novo in 1991 and became CEO in 2017, will stay on for a transition period, the company said.A search for his successor is underway. “Novo Nordisk’s strategy remains ...